Leveraging Next Generation Sequencing (NGS) technology, this expanded 50-gene panel can detect nearly 200 different variants and provides recommendations for over 220 associated drugs. The recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The PGxOne™ Plus report also provides information related to drug-to-drug, drug-to-food, drug-to-alcohol and drug-to-laboratory test interactions that are relevant to a patient’s current medications. Thus, test results offer physicians a valuable tool for guiding effective treatment decisions and potentially reducing trial-and-error treatment selection and adverse drug events.
“Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions and understands that Concierge Medicine is the ideal mechanism for delivering the industry’s most comprehensive pharmacogenomics test,” said Brady Millican, Vice President, Admera Health.
“What would happen if physicians could begin making treatment recommendations based upon a patient’s genotype?” said Catherine Sykes, CEO/Publisher of Concierge Medicine Today. “Concierge Doctors are in the habit of spending an inordinate amount of time with their patients, many of whom have significant and serious health issues. What would happen if we intentionally connected [Concierge] physicians with new scientific technologies that could enable them to deliver better precision treatment recommendations and provide more accurate prescribing to their patients? We aim to find out.”
“Pharmacogenomics is vanguard science which allows physicians to target an individual with the very best personalized therapy based on their own genetic information,” said Zeil Rosenberg, M.D., Vice President, Medical Affairs, Admera Health. “Thanks to major advances in medicine and information by patients, this knowledge translates into clear and immediate clinical benefits.”
“This is an important next step in medicine,” said Sykes. “It is critical that patients and their advising physician(s) begin to learn more about a person’s individual genome. Medical science is advancing more rapidly than we’ve ever seen, outpacing what a physician can possibly know about adverse drug interactions based on genotype. There are tests available and becoming increasingly more affordable that determine how patients will respond to drug therapy for a number of therapeutic areas, including psychiatry, pain management and cardiology.”
Patients need only to be tested once, as genetic information does not change over time. Therefore, these results have lifetime utility. As hospitals implement clinical pharmacogenomics testing programs in the coming years, more physicians will be able to utilize this valuable information to guide drug management and provide better patient care.